Agilent Technologies, BIA Separations GmbH sign agreement giving Agilent access to BIA Separations' bio-monolitic technology
Agilent Technologies Inc. and BIA Separations GmbH announced the signing of an agreement that gives Agilent access to BIA Separations' bio-monolithic technology. Agilent plans to commercialize analytical HPLC bio-monolith columns with strong and weak ion-exchange phases and a Protein A phase. BIA Separations currently provides their preparative scale CIM(r) disk and process scale CIM(r) tube bio-monolithic products for purification and bioconversion of bio-molecules.
"Having access to the bio-monolithic technology allows Agilent to provide enabling solutions for the analytical separation of virus particles, plasmid DNA, antibodies and other macro bio-molecules," said Helen Stimson, vice president and general manager of Agilent's Global Columns and Supplies Solutions. "This technology, when applied at the analytical scale, will improve bio-drug characterization in development and allow QA/QC and process control labs to better monitor and characterize the production of biologics."
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.